Xenon Pharmaceuticals (XENE) Accumulated Depreciation (2021 - 2025)

Xenon Pharmaceuticals (XENE) has 5 years of Accumulated Depreciation data on file, last reported at $15.4 million in Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 14.74% year-over-year to $15.4 million in Q4 2025; TTM through Dec 2025 was $15.4 million, a 14.74% increase from a year earlier, with the FY2025 full-year figure at $15.4 million, up 14.74% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $15.4 million, up from $13.5 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for XENE reached as high as $15.4 million in Q4 2025 and fell as low as $8.7 million in Q4 2022.
• Historically, Accumulated Depreciation has averaged $12.4 million across 5 years, with a median of $13.4 million in 2021.
• Across the five-year window, Accumulated Depreciation sank 34.79% in 2022 and gained 29.25% in 2023, its largest moves.
• Year by year, Accumulated Depreciation stood at $13.4 million in 2021, then sank by 34.79% to $8.7 million in 2022, then climbed by 29.25% to $11.3 million in 2023, then rose by 19.67% to $13.5 million in 2024, then advanced by 14.74% to $15.4 million in 2025.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $15.4 million in Q4 2025, $13.5 million in Q4 2024, and $11.3 million in Q4 2023.